Immune Checkpoint Blockade (ICB) has revolutionized the treatment of cancers like melanoma, but up to 60% of patients don't ...
TOKYO -- Over 90% of physicians deny the scientific efficacy of nonstandard cancer treatments not covered by public medical ...
Doctors at Boston’s Beth Israel share how CAR T cell therapy and other emerging immune therapies are delivering promising ...
Seventy-five percent of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) who were treated with the antibody ...
Pivekimab Sunirine shows a 75% complete response rate in BPDCN patients in the CADENZA trial, offering new hope for rare ...
Bria-IMT demonstrates a median overall survival of 15.6 months, surpassing historical data for heavily pretreated metastatic breast cancer patients. The therapy is well-tolerated, with no treatment ...
At Beth Israel Deaconess Medical Center, doctors say a once-fringe treatment for multiple myeloma is starting to look like a legitimate frontline weapon for some patients. CAR T cell therapy is ...
A phase 2, multicenter, open-label study of AlloStim combined with anti-PD-L1 immunotherapy as 4L therapy in patients with MSS/pMMR metastatic colorectal cancer. This is an ASCO Meeting Abstract from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results